Alyeska Investment Group
NKTR icon

Alyeska Investment Group’s Nektar Therapeutics NKTR Stock Holding History

Alyeska Investment Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.6M Buy
+50,000
New +$2.85M 0.01% 509
2024
Q2 		– Sell
-71,285
Closed -$999K – 640
2024
Q1 		$999K Sell
71,285
-163,333
-70% -$1.71M 0.01% 413
2023
Q4 		$1.99M Buy
234,618
+145,837
+164% +$1.1M 0.01% 369
2023
Q3 		$793K Buy
+88,781
New +$855K 0.01% 430

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's NKTR Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 50,000 shares worth $3.6M. The stake represents 0.01% of the portfolio and ranks #509 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in NKTR as recently as Q1 2024.

Alyeska Investment Group first reported a position in NKTR in Q3 2023 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Alyeska Investment Group held 50,000 shares of Nektar Therapeutics worth $3.6M as of Q1 2026.
  • Nektar Therapeutics was a new Alyeska Investment Group position in Q1 2026.
  • Nektar Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #509 holding.
  • Alyeska Investment Group first reported a position in Nektar Therapeutics in Q3 2023 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.